Document is current
Any future updates will be listed below
-
Authors
Min, Mildred https://orcid.org/0000-0002-6201-7401
Afzal, Nasima
Maloh, Jessica
Dulai, Ajay S.
Ahmad, Nabeel
Pinzauti, David
Sivamani, Raja K.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05919810 at ClinicalTrials.govDocuments that mention this clinical trial
Prospective Comparative Study of an Oral Synbiotic and a Myoinositol-Based Herbal Supplement in Modifying Hormone Levels and the Gut Microbiome in Non-cystic Acne
https://doi.org/10.1007/s13555-025-01411-4
-
Funding
Funding for this research was provided by:
Codex Labs
- License Information
-
More Information
Article History
Received: 11 February 2025
Accepted: 6 April 2025
First Online: 18 April 2025
Declarations
:
: Jessica Maloh serves as a consultant and stockholder for Codex Labs. Raja K. Sivamani serves as a scientific advisor and a holder of stock options with Codex Labs, a scientific advisor to Arbonne, and as a consultant to Burt’s Bees, Novozymes, Nutrafol, Abbvie, Leo, Galderma, Pfizer, UCB, Incyte, Sanofi, Novartis, Arcutis, Amgen, Sun and Regeneron Pharmaceuticals. Mildred Min, Nasima Afzal, Ajay Dulai, Nabeel Ahmad, and David Pinzauti report no conflict of interest.
: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Allendale Institutional Review Board (CB_Acne_Supp) on June 26, 2023. Written informed consent and assent (where appropriate) was obtained from all subjects and/or guardians involved in the study.
